SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis

Summary

This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. Investigators will assess whether treatment is associated with changes in liver-related clinical measures, biologic markers, and other study outcomes relevant to disease progression. The goal of this study is to generate early data to determine whether SAMe should be studied further as a potential therapeutic strategy in patients with MASLD cirrhosis.

Timeline

Start

2026-04-15

Primary completion

2030-12-31

Completion

2031-12-31

Drugs

Indications